6月26日，Twist Bioscience盘中上涨5.41%，报102.33美元/股，成交额6027.62万美元，股价在突破Canaccord Genuity此前给予的90美元目标价后持续加速上行。
消息面上，公司此前提交至多2亿美元普通股货架注册声明引发的稀释担忧已被市场充分消化，叠加Canaccord Genuity给予买入评级及90美元目标价（显著高于市场共识目标价73.12美元），多家投行上调评级形成合力，推动股价连续三个交易日放量反弹并突破目标位后进一步走高。
Twist Bioscience是一家合成生物学平台公司，开发基于硅芯片的DNA合成技术，服务于医疗健康、食品农业、工业化学品及数据存储等领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.